The CFR was significantly higher in T2DM patients receiving insulin and SU and significantly lower in those taking metformin, DPP-4 inhibitors, SGLT2 inhibitors, and arGLP-1 (on therapy vs. no therapy) before the viral disease (Table 3). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.